News
Latest update
In this episode, Joe interviews Deborah C. Mash, Ph.D.: neuroscientist; Professor Emerita of Neurology and Molecular and Cellular Pharmacology at the University …
Jun 09, 2023 (AB Digital via COMTEX) — The Opium Addiction market growth is driven by factors like increase in the prevalence …
The Kentucky Opioid Abatement Advisory Commission held its first public hearing Monday, July 17, to discuss funding development of an opioid-use disorder treatment using …
Today, Daniel Cameron, Attorney General for the US State of Kentucky, announced that the State will take $42 million from its portion …
Deborah Mash is Professor of Neurology (Emeritus) and Molecular and Cellular Pharmacology at the University of Miami Miller School of Medicine. She …
If you or a loved one struggle with addiction, this is an episode you’re going to want to listen to. Many of …
Source: https://www.benzinga.com/markets/cannabis/22/06/27799330/10-psychedelics-ceos-to-pay-attention-to-in-2022-1 2020 and 2021 were defining years for the burgeoning psychedelics industry. In 2021 alone, more than $730 million were invested into various …
People seeking treatment to overcome opioid addiction are often stymied by the treatment itself. Many don’t have access to drugs like methadone …
Anne Phillipi of The New Health Club presents Dr. Deborah Mash – ibogaine can make you review your life Posted at 12:01h in Podcast by demerx …
DemeRx IB, Inc. CEO Deborah Mash joined Proactive New York to discuss the group’s joint venture with Atai Life Sciences (NASDAQ:ATAI), focused …
Source: https://www.healtheuropa.com/could-ibogaine-offer-a-revolutionary-long-term-solution-to-addiction/100635/ Derived from the iboga plant, ibogaine is a psychoactive compound that could have huge potential as a long-term solution to …
Yale Psychedelics Science Group presents Dr. Deborah Mash – Breaking the Cycle of Opioid Dependence with ibogaine Watch full webinar:
Today’s episode features Deborah Mash, founder and CEO of DemeRx, a clinical stage company developing ibogaine therapies to treat substance use disorders. In this …
A joint venture between DemeRx and Atai Life Sciences has been cleared by the UK Medicines and Healthcare products Regulatory Agency (MHRA) …
NEW YORK, March 10, 2021 /PRNewswire/ — DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment …
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the launch of a Phase I/IIa trial of DemeRx and atai …
2020 has been a tough year for global markets and this is a trend that we have been closely following. During the …
CEO and co-founder of ATAI Life Sciences, Florian Brand explains why one psychedelic medicine might provide the key to fighting opioid addiction. …
“ibogaine made them ready for change,” says researcher Deborah Mash, PhD. Mash has been studying the effects of ibogaine since 1992. A psychedelic …
BERLIN and MIAMI, Jan. 24, 2020 /PRNewswire/ — ATAI Life Sciences AG (“ATAI” or the “Company”), a global biotech platform that envisions an end to mental illnesses, today announced …
INTERNATIONAL – The World Economic Forum’s billionaire audience in Davos took a break from the problem of climate change to listen to …
Ira Pastor, ideaXme exponential health ambassador and founder of Bioquark interviews Dr. Deborah Mash, Professor of Neurology and Molecular and Cellular Pharmacology at the Leonard M. Miller School …
The United States is struggling with a staggering opioid addiction epidemic—often starting with legitimate pain pill prescriptions, and ending with full-blown abuse. …
When Dr. Deborah Mash met the grandfather of ibogaine treatment, Howard Lotsof, and observed first-hand the effectiveness that ibogaine had for addiction …
Heroin addicts and alcoholics have said ibogaine helped them kick addiction, so why is it illegal in the United States? Read full …
News from Kron 4, San Fransisco. Dr. Mash is one of the few scientists in the world to study ibogaine, a mild …
